Update on the emerging role of telavancin in hospital-acquired infections Article

Full Text via DOI: 10.2147/TCRM.S57376 PMID: 25926737 Web of Science: 000352777600001
Open Access

Cited authors

  • Nnedu, Obinna N.; Pankey, George A.


  • Telavancin is a lipoglycopeptide that has activity against Gram-positive aerobic and anaerobic bacteria. It has activity against methicillin-resistant Staphylococcus aureus, vancomycin-intermediate S. aureus and non-Van-A strains of vancomycin-resistant enterococci. It has been approved by the US Food and Drug Administration (FDA) for complicated skin and skin structure infections and hospital-acquired pneumonia. There is a need for more clinical studies to determine the role of telavancin in treating bacteremia and prosthetic device infections. In this review, we discuss the published data on the use of telavancin in treating hospital-acquired infections and provide an update on new research.

Publication date

  • 2015


International Standard Serial Number (ISSN)

  • 1178-203X

Start page

  • 605

End page

  • 610


  • 11